Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$10.49 USD
+0.51 (5.11%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $10.31 -0.18 (-1.72%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SMMT 10.49 +0.51(5.11%)
Will SMMT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SMMT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SMMT
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
SMMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Other News for SMMT
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
Ivonescimab’s Promising Trial Results and Potential Market Impact: A Strong Buy Recommendation
Citi opens 'positive catalyst watch' on Summit Therapeutics
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)